Biotechnology Value Fund L P's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Jun 26, 2026
- Accession no.
- 0000921895-26-001688
- Filed
- Jun 26, 2026, 6:48 PM ET
- Trade date
- Jun 26, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $173.7M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | Director, Other: See Remarks and Footnotes |
| BVF Partners L PCIK 0001055947 | Director, Other: See Remarks and Footnotes |
| BVF IncCIK 0001056807 | Director, Other: See Remarks and Footnotes |
| Biotechnology Value Fund II LPCIK 0001102444 | Director, Other: See Remarks and Footnotes |
| Lampert Mark NCIK 0001233840 | Director, Other: See Remarks and Footnotes |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Director, Other: See Remarks and Footnotes |
| BVF Partners OS Ltd.CIK 0001660684 | Director, Other: See Remarks and Footnotes |
| BVF I GP LLCCIK 0001803805 | Director, Other: See Remarks and Footnotes |
| BVF II GP LLCCIK 0001803806 | Director, Other: See Remarks and Footnotes |
| BVF GP Holdings LLCCIK 0001803809 | Director, Other: See Remarks and Footnotes |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Common Stock, $0.0001 par value | SSaleDisposed | −837,914 | $106.50 | −$89,237,841 | 1,960,881 | Direct | |
| Jun 26, 2026 | Common Stock, $0.0001 par value | SSaleDisposed | −627,597 | $106.50 | −$66,839,080.5 | 1,592,261 | Direct | |
| Jun 26, 2026 | Common Stock, $0.0001 par value | SSaleDisposed | −113,289 | $106.50 | −$12,065,278.5 | 240,123 | Direct | |
| Jun 26, 2026 | Common Stock, $0.0001 par value | SSaleDisposed | −51,858 | $106.50 | −$5,522,877 | 78,787 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.